Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 2/20 | 0.73 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.73 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.73 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 11/20 | 0.61 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL185452 | 0.88 | HCAR3 (0.64) | HDAC3HDAC1HDAC2HDAC6MAPK1 | |
| SCHEMBL16047037 | 0.86 | HCAR3 (0.62) | HDAC3HDAC1HDAC2HDAC6MAPK1 | |
| SCHEMBL13736219 | 0.86 | HDAC3 (0.71) | HDAC3HDAC1HDAC2HDAC6MAPK1 | |
| SCHEMBL4729665 | 0.84 | HDAC6 (1.00) | HDAC3HDAC1HDAC2HDAC6MAPK1 | |
| SCHEMBL17624689 | 0.84 | HDAC3 (0.64) | HDAC3HDAC1HDAC2HDAC6MAPK1 | |
| SCHEMBL30693042 | 0.82 | HCAR3 (0.57) | HDAC3HDAC1HDAC2HDAC6MAPK1 | |
| SCHEMBL13015030 | 0.81 | HDAC1 (0.53) | HDAC3HDAC1HDAC2HDAC6HCAR3 | |
| Hydrochloric Acid SCHEMBL3774411 | 0.79 | HDAC1 (0.52) | HDAC3HDAC1HDAC2HDAC6HCAR3 | |
| SCHEMBL14676324 | 0.79 | MAPK1 (0.56) | MAPK1CSNK2A1 | |
| SCHEMBL17832701 | 0.78 | HDAC1 (0.55) | HDAC3HDAC1HDAC2HDAC6HCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230110165-A1 | Substituted Imidazo[4,5-c]pyridine Compounds and Compositions Thereof | PROXIMAGEN LLC (US) | 2023-04-13 | — | — | US | disclosed |
| US-11512082-B2 | Substituted imidazo[4,5-c]pyridine compounds and compositions thereof | PROXIMAGEN, LLC (US) | 2022-11-29 | — | — | US | disclosed |
| US-10968223-B2 | Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors | PROXIMAGEN, LLC (US) | 2021-04-06 | — | — | US | disclosed |
| US-10968223-B2 | Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors | PROXIMAGEN, LLC (US) | 2021-04-06 | — | — | US | disclosed |
| US-20200347059-A1 | IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS | PROXIMAGEN, LLC (US) | 2020-11-05 | — | — | US | disclosed |
| US-20200347059-A1 | IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS | PROXIMAGEN, LLC (US) | 2020-11-05 | — | — | US | disclosed |
| US-10766897-B2 | Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors | PROXIMAGEN, LLC (US) | 2020-09-08 | — | — | US | disclosed |
| US-10766897-B2 | Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors | PROXIMAGEN, LLC (US) | 2020-09-08 | — | — | US | disclosed |
| US-20200262835-A1 | COMPOUNDS | PROXIMAGEN, LLC (US) | 2020-08-20 | — | — | US | disclosed |
| US-10590125-B2 | Compounds | PROXIMAGEN, LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-9428498-B2 | Substituted imidazo[4,5-c]pyridine compounds and compositions thereof | PROXIMAGEN LIMITED (GB) | 2016-08-30 | — | — | US | disclosed |
| WO-2016042331-A1 | IMIDAZO[4,5-C]PYRIDINE DERIVED SSAO INHIBITORS | PROXIMAGEN LIMITED (GB) | 2016-03-24 | — | — | WO | disclosed |
| US-20160046622-A1 | IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS | PROXIMAGEN, LLC | 2016-02-18 | — | — | US | disclosed |
| EP-2970260-A1 | IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS | Proximagen Limited (GB) | 2016-01-20 | — | — | EP | disclosed |
| US-20150258101-A1 | NEW COMPOUNDS | PROXIMAGEN LIMITED (GB) | 2015-09-17 | — | — | US | disclosed |
| US-20150258101-A1 | NEW COMPOUNDS | PROXIMAGEN LIMITED (GB) | 2015-09-17 | — | — | US | disclosed |
| WO-2014140592-A1 | IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS | PROXIMAGEN LIMITED (GB) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014140592-A1 | IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS | PROXIMAGEN LIMITED (GB) | 2014-09-18 | — | — | WO | disclosed |
| US-20140275040-A1 | NEW COMPOUNDS | PROXIMAGEN LIMITED (GB) | 2014-09-18 | — | — | US | disclosed |
| US-20140275040-A1 | NEW COMPOUNDS | PROXIMAGEN LIMITED (GB) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10590125-B2 | Compounds | ALOX15B, ALOX12, ALOX15 | HDAC3 2894/4885HDAC1 1649/4885HDAC2 1544/4885 |
| US-11512082-B2 | Substituted imidazo[4,5-c]pyridine compounds and compositions thereof | PNPO, XDH, EPX | HDAC3 629/4885HDAC1 481/4885HDAC2 1410/4885 |
| US-10766897-B2 | Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors | PNPO, SSB, XDH | HDAC3 1948/4885HDAC1 699/4885HDAC2 1841/4885 |
| US-20140275040-A1 | NEW COMPOUNDS | SSB, ALOX15B, ALOX12 | HDAC3 3108/4885HDAC1 1874/4885HDAC2 1865/4885 |
| US-10968223-B2 | Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors | PNPO, PPOX, SCO2 | HDAC3 2167/4885HDAC1 1019/4885HDAC2 1846/4885 |
| US-20230110165-A1 | Substituted Imidazo[4,5-c]pyridine Compounds and Compositions Thereof | PNPO, XDH, EPX | HDAC3 629/4885HDAC1 481/4885HDAC2 1410/4885 |
| US-20200347059-A1 | IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS | PNPO, PPOX, SCO2 | HDAC3 2167/4885HDAC1 1019/4885HDAC2 1846/4885 |
| US-20160046622-A1 | IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS | PNPO, AOC3, IL4I1 | HDAC3 1649/4885HDAC1 270/4885HDAC2 423/4885 |
| US-20200262835-A1 | COMPOUNDS | QSOX1, AOX1, EPX | HDAC3 687/4885HDAC1 318/4885HDAC2 1121/4885 |
| US-20150258101-A1 | NEW COMPOUNDS | AOX1, QSOX1, MAOB | HDAC3 1827/4885HDAC1 562/4885HDAC2 1291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.